The Aporia · U.S. waives tariffs on certain speciality drugs from 20 countries, including India

U.S. waives tariffs on certain speciality drugs from 20 countries, including India

Read the original at The Hindu ↗

Cite

APA MLA Chicago

U.S. waives tariffs on certain speciality drugs from 20 countries, including India. (2026, September 29). The Hindu. https://www.thehindu.com/news/international/us-waives-tariffs-on-certain-speciality-drugs-from-20-countries-including-india/article71522910.ece

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Quick Summary

The U.S. Commerce Department has announced it will waive ad valorem tariffs on certain specialty drugs and related components from India and 19 other countries for treatments of rare diseases and other specific medical conditions. This exemption is part of President Trump’s April proclamation to impose a 100% tariff on specified patented pharmaceuticals starting September 29, but excludes these designated products under Section 232 of the Trade Expansion Act. The list includes countries with trade and security agreements with the U.S., such as India, Japan, South Korea, and several European nations.

Written by AI on 2026-09-29, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

On April 2, President Donald Trump issued a proclamation to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S., as part of efforts to encourage domestic production. However, in response, the U.S. Commerce Department announced that certain speciality drugs and their components from rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals will be exempted from tariffs starting September 29. The tariff exemption applies to imports from India and 19 other countries, including Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, among others. These drugs used for treating rare medical conditions are subject to a zero percent ad valorem tariff rate in the U.S., effectively waiving tariffs on these critical pharmaceuticals from the listed nations.

Written for “US Tariff Waiver Drugs India” on 2026-11-03, grounded in this article and the 1 other(s) covering the same event.

Compared with similar articles

This article reads unscored and hedges 27% of its claims. Each row says how that neighbour differs.

U.S. waives tariffs on certain speciality drugs from 20 countries, including India Same event

The Hindu

Hedges 3 of 11 claims Outlet record 60/100

How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

27%

3 of 11 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

60/100

The Hindu's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Economy/Business

Same framing elsewhere

articles that frame the event the way this one does

Analyzed 2026-09-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability

Source leaning vs. consistency

Publisher

The Hindu · 907 article(s) · 2 correction(s) detected

Running correction rate · 2 correction(s)

2026-10-05

Trump cites Indian election that didn't happen to call U.S. electoral process ‘corrupt’

2026-10-04

Tennessee’s prisons chief is resigning after failed execution of Christa Pike

Who wrote this

No reporter is named on this article, beyond the feed's “PTI”.

Topics

India Section 232 The U.S. Commerce Department U.S. the World Customs Organisation

Subjects

U.S. GPE · 3× India GPE · 2× Argentina GPE · 1× Bangladesh GPE · 1× Cambodia GPE · 1× Donald Trump PERSON · 1× Ecuador GPE · 1× The U.S. Commerce Department ORG · 1× the Federal Register ORG · 1× the World Customs Organisation ORG · 1×

Narrative

On April 2, President Donald Trump issued a proclamation to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S. as part of efforts to encourage domestic production.

framing: mixed · carried by 2 article(s) · first seen 2026-09-29

🔮 The U.S. will not charge any ad valorem tariff on certain speciality drugs and associated ingredients used for treatment of rare medical conditions imported from India and 19 other countries.

2026-09-29 · The Hindu

U.S. waives tariffs on certain speciality drugs from 20 countries, including India · mixed framing

2026-09-29 · The Hindu

U.S. waives tariffs on certain speciality drugs from 20 countries, including India · mixed framing

Claims (11 extracted, 3 hedged)

The U.S. will not charge any ad valorem tariff on certain speciality drugs and associated ingredients used for treatment of rare medical conditions imported from India and 19 other countries. asserted

U.S. → charge → India

An ad valorem tariff is a set percentage of the monetary value of the goods to be taxed, according to the World Customs Organisation. uncertain

tariff → set → Organisation

The U.S. Commerce Department published the list of countries in the Federal Register as it prepares to impose a 100% tariff on certain patented pharmaceutical imports and their associated ingredients from September 29. asserted

it → publish → September

Trump → issue → production

Eligible products for the zero per cent tariff rate include all drugs designated for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals. asserted

products → include → diseases

The notice said qualifying products from these jurisdictions could receive a zero per cent tariff because they have a current or forthcoming trade and security framework agreement with the U.S. The exemptions are part of the implementation of Trump’s April proclamation adjusting imports of pharmaceuticals and pharmaceutical ingredients under Section 232 of the Trade Expansion Act. uncertain

exemptions → say → Act

The proclamation imposed a 100% tariff on specified patented pharmaceuticals and ingredients. asserted

proclamation → impose → pharmaceuticals

It took effect on July 31 for companies named in one annex and will apply to other covered companies from September 29. asserted

It → take → September

Generic pharmaceutical products and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs, according to the Commerce Department notice. uncertain

products → associate → notice

The notice also makes several technical corrections to the original proclamation, including amending the definition of “generic pharmaceutical articles” to specifically include unpatented animal health products. asserted

notice → make → products

It also clarifies that the definition of “pharmaceutical articles” only encompasses finished pharmaceutical products, their active pharmaceutical ingredients, and the key starting materials of such ingredients. asserted

definition → clarify → ingredients